Q3 Earnings Forecast for Pharvaris Issued By HC Wainwright

Key Points

• HC Wainwright predicts Pharvaris N.V. will report a Q3 2025 earnings per share of ($0.69), with a "Buy" rating and a price target of $60.00.
• Other brokers have mixed ratings for Pharvaris, with Bank of America upgrading it to "neutral" and raising the price target to $27.00, while Weiss Ratings maintained a "sell (d-)" rating.
• Large investors are increasing their stakes in Pharvaris, with significant purchases from firms like JPMorgan Chase & Co. and BNP Paribas Asset Management.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Pharvaris in a research report issued on Wednesday, October 15th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.69) per share for the quarter. HC Wainwright has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris' Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.31) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.42) EPS, FY2027 earnings at ($2.67) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at $2.22 EPS.

A number of other brokerages have also commented on PHVS. Bank of America upgraded Pharvaris from an "underperform" rating to a "neutral" rating and increased their price objective for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a research report on Wednesday, August 13th. Zacks Research upgraded Pharvaris from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Pharvaris presently has an average rating of "Moderate Buy" and a consensus price target of $37.17.

Pharvaris Price Performance

NASDAQ PHVS opened at $21.86 on Friday. The firm has a market cap of $1.14 billion, a PE ratio of -6.51 and a beta of -2.77. The stock's 50 day simple moving average is $23.01 and its 200 day simple moving average is $19.31. Pharvaris has a one year low of $11.51 and a one year high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Pharvaris in the 2nd quarter valued at $57,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc lifted its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after purchasing an additional 1,695 shares during the period. Palumbo Wealth Management LLC lifted its stake in shares of Pharvaris by 38.0% in the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock valued at $221,000 after purchasing an additional 3,881 shares during the period. Finally, California State Teachers Retirement System raised its stake in Pharvaris by 9.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company's stock worth $247,000 after buying an additional 1,257 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.